Minimal-Change Nephrotic Syndrome Associated with Systemic Lupus Erythematosus

1995 ◽  
Vol 15 (5) ◽  
pp. 439-441 ◽  
Author(s):  
Hirofumi Makino ◽  
Toshinori Haramoto ◽  
Kenichi Shikata ◽  
Toshio Ogura ◽  
Zensuke Ota
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Nephrotic Syndrome ◽  
Lupus Erythematosus ◽  
Minimal Change Nephrotic Syndrome ◽  
Minimal Change ◽  
Systemic Lupus

scholarly journals Minimal change nephrotic syndrome associated with systemic lupus erythematosus

2005 ◽  
Vol 21 (1) ◽  
pp. 230-230 ◽  
Author(s):  
Taro Horino ◽  
Toshihiro Takao ◽  
Tatsuhito Morita ◽  
Hiroyuki Ito ◽  
Kozo Hashimoto
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Nephrotic Syndrome ◽  
Lupus Erythematosus ◽  
Minimal Change Nephrotic Syndrome ◽  
Minimal Change ◽  
Systemic Lupus

scholarly journals Minimal Change Disease as a Secondary and Reversible Event of a Renal Transplant Case with Systemic Lupus Erythematosus

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Elena Gkrouzman ◽  
Kyriakos A. Kirou ◽  
Surya V. Seshan ◽  
James M. Chevalier
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Nephrotic Syndrome ◽  
Renal Transplant ◽  
Transplant Recipient ◽  
Lupus Erythematosus ◽  
Minimal Change Disease ◽  
Iliac Vein ◽  
Minimal Change ◽  
Systemic Lupus ◽  
Vein Stenosis

Secondary causes of minimal change disease (MCD) account for a minority of cases compared to its primary or idiopathic form and provide ground for consideration of common mechanisms of pathogenesis. In this paper we report a case of a 27-year-old Latina woman, a renal transplant recipient with systemic lupus erythematosus (SLE), who developed nephrotic range proteinuria 6 months after transplantation. The patient had recurrent acute renal failure and multiple biopsies were consistent with MCD. However, she lacked any other features of the typical nephrotic syndrome. An angiogram revealed a right external iliac vein stenosis in the region of renal vein anastomosis, which when restored resulted in normalization of creatinine and relief from proteinuria. We report a rare case of MCD developing secondary to iliac vein stenosis in a renal transplant recipient with SLE. Additionally we suggest that, in the event of biopsy-proven MCD presenting as an atypical nephrotic syndrome, alternative or secondary, potentially reversible, causes should be considered and explored.

scholarly journals A patient with systemic lupus erythematosus and lupus nephritis: A 12-year follow-up

2011 ◽  
Vol 68 (8) ◽  
pp. 705-708
Author(s):  
Natasa Jovanovic ◽  
Jasmina Markovic-Lipkovski ◽  
Stevan Pavlovic ◽  
Biljana Stojimirovic
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Nephrotic Syndrome ◽  
Mycophenolate Mofetil ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Kidney Biopsy ◽  
Immunosuppressive Drugs ◽  
Systemic Lupus ◽  
Younger Women ◽  
The Right

Introduction. Systemic lupus erythematosus (SLE) is a chronic immunological disease causing a significant morbidity and mortality in younger women and involving several organs and systems, most often the kidneys, being consequently the incidence of lupus nephritis (LN) about 60%. Case report. We reported a 57 year-old patient with the diagnosed SLE in 1995. Pathohistological analysis of kidney biopsy revealed LN type V. The patient was treated with corticosteroid pulses and azathioprine during one year. A remission was achieved and maintained with prednisone, 15 mg daily. Nephrotic relapse was diagnosed in 2006 and the second kidney biopsy revealed recent kidney infarction due to extensive vasculitis. Soon, a cerebrovascul insult developed and CT-scan revealed endocranial infarctus. The patient was treated with corticosteroids and cyclophosphamide pulses (totally VI monthly pulses), and also with low-molecular heparine, anticoagulants and salicylates because of the right leg phlebothrombosis. After the pulses, the patient was adviced to take prednisone 20 mg daily and azothioprine 100 mg daily, and 6 months later mycophenolate mofetil because of persistent active serological immunological findings (ANA 1 : 320) and nephrotic syndrome. Mycophenolate mofetil was efficient in inducing and maintaining remission of nephrotic syndrome. Conclusion. The aim of LN treatment is to achieve and maintain remission, improve patients? outcome, reduce the toxicity of immunosuppressive drugs and the incidence of relapses. Mycophenolate mofetil was shown to be efficient in inducing and maintaining remission of nephrotic syndrome in the frame of LN.

Membranous nephropathy

2010 ◽  
pp. 3985-3988
Author(s):  
Dwomoa Adu
Keyword(s):  
Prostate Cancer ◽  
Systemic Lupus Erythematosus ◽  
Nephrotic Syndrome ◽  
Basement Membrane ◽  
Autoimmune Diseases ◽  
Outer Surface ◽  
Glomerular Basement Membrane ◽  
Lupus Erythematosus ◽  
Membranous Nephropathy ◽  
Systemic Lupus

Membranous nephropathy, which accounts for 20 to 30% of cases of the nephrotic syndrome in adults, is defined histologically by the presence of subepithelial immune deposits on the outer surface of the glomerular basement membrane. The immune mechanisms that lead to this are uncertain, and most cases are of unknown cause (idiopathic), but the condition can be associated with autoimmune diseases (systemic lupus erythematosus), malignancy (in 10% of cases, most commonly lung and prostate cancer), drugs, and infections....

Sign in / Sign up

Export Citation Format

Share Document